PROTHENA CORPORATION PUBLIC LIMITED COMPANY Stock Issued During Period, Value, New Issues
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- PROTHENA CORPORATION PUBLIC LIMITED COMPANY stock issued during period, value, new issues for the quarter ending 2021-03-31 was $78.05M.
- PROTHENA CORPORATION PUBLIC LIMITED COMPANY stock issued during period, value, new issues for the quarter ending 2018-12-31 was $0.00.
- PROTHENA CORPORATION PUBLIC LIMITED COMPANY stock issued during period, value, new issues for the quarter ending 2018-09-30 was $0.00.
- PROTHENA CORPORATION PUBLIC LIMITED COMPANY stock issued during period, value, new issues for the quarter ending 2018-06-30 was $0.00.
- PROTHENA CORPORATION PUBLIC LIMITED COMPANY stock issued during period, value, new issues for fiscal 2018 was $39.76M, a 73.55% decline from fiscal 2017.
- PROTHENA CORPORATION PUBLIC LIMITED COMPANY stock issued during period, value, new issues for fiscal 2017 was $150.32M, a 16.86% increase from fiscal 2016.
- PROTHENA CORPORATION PUBLIC LIMITED COMPANY stock issued during period, value, new issues for fiscal 2016 was $128.64M, a 2.16% decline from fiscal 2015.
- PROTHENA CORPORATION PUBLIC LIMITED COMPANY stock issued during period, value, new issues for fiscal 2015 was $131.48M, a 11.97% increase from fiscal 2014.
| Period end | Stock Issued During Period, Value, New Issues 3 month | Stock Issued During Period, Value, New Issues 12 month |
|---|---|---|
| 2021-03-31 | $78.05M 10-Q · filed 2021-05-11 | |
| 2018-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-15 | $39.76M 10-K · filed 2019-03-15 |
| 2018-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-05 | |
| 2018-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-06 | |
| 2018-03-31 | $39.76M 10-Q · filed 2019-05-07 | |
| 2017-12-31 | $150.32M 10-K · filed 2020-03-03 | |
| 2016-12-31 | $128.64M 10-K · filed 2019-03-15 | |
| 2015-12-31 | $131.48M 10-K · filed 2018-02-26 | |
| 2014-12-31 | $117.43M 10-K · filed 2017-02-27 | |
| 2013-12-31 | $84.45M 10-K · filed 2016-02-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 | |
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| MapLight Therapeutics, Inc. (MPLT) | United States | $0.459B | -7.10 |